RU2009120990A - Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции - Google Patents
Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции Download PDFInfo
- Publication number
- RU2009120990A RU2009120990A RU2009120990/15A RU2009120990A RU2009120990A RU 2009120990 A RU2009120990 A RU 2009120990A RU 2009120990/15 A RU2009120990/15 A RU 2009120990/15A RU 2009120990 A RU2009120990 A RU 2009120990A RU 2009120990 A RU2009120990 A RU 2009120990A
- Authority
- RU
- Russia
- Prior art keywords
- testosterone
- ht1a
- sexual dysfunction
- pharmaceutical composition
- composition
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims abstract 42
- 229960003604 testosterone Drugs 0.000 title claims abstract 21
- 239000003723 serotonin 1A agonist Substances 0.000 title claims abstract 12
- 201000001880 Sexual dysfunction Diseases 0.000 title claims abstract 8
- 231100000872 sexual dysfunction Toxicity 0.000 title claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 10
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims abstract 8
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims abstract 8
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims abstract 8
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims abstract 8
- 230000001568 sexual effect Effects 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 206010057671 Female sexual dysfunction Diseases 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
1. Применение тестостерона и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается, по существу, за один час и указанный тестостерон - за 3,5-5,5 ч до сексуальной активности. ! 2. Применение тестостерона, ингибитора ФДЭ5 и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается, по существу, за один час, указанный ингибитор за 1-2 ч и указанный тестостерон - за 3,5-5,5 ч до сексуальной активности. ! 3. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой женскую сексуальную дисфункцию. ! 4. Фармацевтическая композиция, включающая тестостерон и агонист 5-HT1A, где указанная композиция предназначена для высвобождения, по существу, всего указанного 5-HT1A за один час и указанного тестостерона - за 3,5-5,5 ч до сексуальной активности. ! 5. Фармацевтическая композиция, включающая тестостерон, ингибитор ФДЭ5 и агонист 5-HT1A, где указанная композиция предназначена для высвобождения, по существу, всего указанного 5-HT1A за один час, указанного ингибитора ФДЭ5 - за 1-2 ч и указанного тестостерона - за 3,5-5,5 ч до сексуальной активности. ! 6. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает тестостерон и, по меньшей мере, одну композицию, которая включает агонист 5-НТ1А, где указанный набор дополнительно включает инструкции по введению указанных композиций. ! 7. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает тестостерон, по меньшей мере, одну фармацевтическую композицию, которая включает ингибитор ФДЭ5 и, по меньшей м�
Claims (8)
1. Применение тестостерона и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается, по существу, за один час и указанный тестостерон - за 3,5-5,5 ч до сексуальной активности.
2. Применение тестостерона, ингибитора ФДЭ5 и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается, по существу, за один час, указанный ингибитор за 1-2 ч и указанный тестостерон - за 3,5-5,5 ч до сексуальной активности.
3. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой женскую сексуальную дисфункцию.
4. Фармацевтическая композиция, включающая тестостерон и агонист 5-HT1A, где указанная композиция предназначена для высвобождения, по существу, всего указанного 5-HT1A за один час и указанного тестостерона - за 3,5-5,5 ч до сексуальной активности.
5. Фармацевтическая композиция, включающая тестостерон, ингибитор ФДЭ5 и агонист 5-HT1A, где указанная композиция предназначена для высвобождения, по существу, всего указанного 5-HT1A за один час, указанного ингибитора ФДЭ5 - за 1-2 ч и указанного тестостерона - за 3,5-5,5 ч до сексуальной активности.
6. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает тестостерон и, по меньшей мере, одну композицию, которая включает агонист 5-НТ1А, где указанный набор дополнительно включает инструкции по введению указанных композиций.
7. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает тестостерон, по меньшей мере, одну фармацевтическую композицию, которая включает ингибитор ФДЭ5 и, по меньшей мере, одну композицию, которая включает агонист 5-НТ1А, где указанный набор также включает инструкции по введению указанных композиций.
8. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой мужскую сексуальную дисфункцию.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06076976A EP1925307A1 (en) | 2006-11-03 | 2006-11-03 | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| EP06076976.7 | 2006-11-03 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012125827A Division RU2646447C2 (ru) | 2006-11-03 | 2012-06-20 | ПРИМЕНЕНИЕ АНАЛОГА ТЕСТОСТЕРОНА И АГОНИСТА 5-НТ1а ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОЙ ДИСФУНКЦИИ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009120990A true RU2009120990A (ru) | 2010-12-10 |
| RU2463054C2 RU2463054C2 (ru) | 2012-10-10 |
Family
ID=37846101
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120988/15A RU2464027C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-альфа-андростендиола, необязательно в сочетании с ингибитором фосфодиэстеразы 5, при лечении половой дисфункции |
| RU2009120990/15A RU2463054C2 (ru) | 2006-11-03 | 2007-11-02 | Применение тестостерона и агониста 5-нт1a для лечения сексуальной дисфункции |
| RU2009120992/15A RU2491073C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции |
| RU2012125827A RU2646447C2 (ru) | 2006-11-03 | 2012-06-20 | ПРИМЕНЕНИЕ АНАЛОГА ТЕСТОСТЕРОНА И АГОНИСТА 5-НТ1а ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОЙ ДИСФУНКЦИИ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120988/15A RU2464027C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-альфа-андростендиола, необязательно в сочетании с ингибитором фосфодиэстеразы 5, при лечении половой дисфункции |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120992/15A RU2491073C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции |
| RU2012125827A RU2646447C2 (ru) | 2006-11-03 | 2012-06-20 | ПРИМЕНЕНИЕ АНАЛОГА ТЕСТОСТЕРОНА И АГОНИСТА 5-НТ1а ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОЙ ДИСФУНКЦИИ |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US8575139B2 (ru) |
| EP (5) | EP1925307A1 (ru) |
| JP (8) | JP2010509211A (ru) |
| KR (6) | KR20090115113A (ru) |
| CN (6) | CN101557812A (ru) |
| AU (3) | AU2007314735B2 (ru) |
| BR (3) | BRPI0717963A2 (ru) |
| CA (3) | CA2668317C (ru) |
| CY (1) | CY1117191T1 (ru) |
| DK (1) | DK2086544T3 (ru) |
| ES (1) | ES2561946T3 (ru) |
| HR (1) | HRP20160108T1 (ru) |
| HU (1) | HUE026752T2 (ru) |
| IL (5) | IL198459A (ru) |
| ME (1) | ME02410B (ru) |
| MX (3) | MX2009004696A (ru) |
| NO (3) | NO20092145L (ru) |
| NZ (3) | NZ577393A (ru) |
| PH (2) | PH12014501440A1 (ru) |
| PL (1) | PL2086544T3 (ru) |
| PT (1) | PT2086544E (ru) |
| RS (1) | RS54541B1 (ru) |
| RU (4) | RU2464027C2 (ru) |
| SI (1) | SI2086544T1 (ru) |
| UA (4) | UA100119C2 (ru) |
| WO (3) | WO2008054214A2 (ru) |
| ZA (3) | ZA200903837B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS52945B (sr) | 2004-05-11 | 2014-02-28 | Emotional Brain B.V. | Farmaceutske formulacije i njihova primena u lečenju ženske seksualne disfunkcije |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| CN103648487B (zh) * | 2011-05-13 | 2019-04-19 | Eb Ip希博里塔布斯有限责任公司 | 药物递送系统 |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| JP5828923B2 (ja) | 2014-01-30 | 2015-12-09 | 国立大学法人高知大学 | ニッケル粉の製造方法 |
| EP3108987A4 (en) | 2014-02-21 | 2018-02-07 | Kochi University, National University Corporation | Method for producing nickel powder |
| JP6406613B2 (ja) | 2014-04-15 | 2018-10-17 | 住友金属鉱山株式会社 | 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法 |
| CN103947533B (zh) * | 2014-05-15 | 2015-12-16 | 青岛理工大学 | 生长环境可控的磁化水工厂化豆芽菜生产系统 |
| RU2600845C2 (ru) | 2014-07-04 | 2016-10-27 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3251436A (en) * | 1965-03-16 | 1966-05-17 | Dayton Steel Foundry Co | Spot-type disk brake |
| US3976776A (en) | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| AU577802B2 (en) | 1983-10-17 | 1988-10-06 | Duphar International Research B.V. | Blood-pressure lowering piperazine derivatives |
| US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4640921A (en) * | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US5015646A (en) | 1987-08-28 | 1991-05-14 | Bristol-Myers Squibb Co. | Pharmaceutically useful polymorphic modification of buspirone |
| US4877774A (en) | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
| CA1335106C (en) * | 1989-02-27 | 1995-04-04 | John Mehnert Schaus | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes |
| US5447912A (en) | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
| US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| DE69420746T2 (de) | 1994-06-02 | 2000-06-29 | Dan Riga | Arzneimittel gegen stress, beeinträchtigung und altwerden und verfahren zu ihrer herstellung |
| RU2152787C2 (ru) | 1994-06-02 | 2000-07-20 | Дан Рига | Лекарство против стресса, против снижения уровня активности и против старения и способ его получения |
| US5698560A (en) | 1995-03-01 | 1997-12-16 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivatives |
| TR199700930T2 (xx) | 1995-03-14 | 1998-07-21 | Vivus Incorporated | Ereksiyon bozuklu�unu �nlemek i�in y�ntem ve kit. |
| US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| WO1996036339A2 (en) * | 1995-05-15 | 1996-11-21 | Beth Israel Hospital | Use of dihydrotestosterone compounds for treating male sexual dysfunction |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6251436B1 (en) * | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
| US6242198B1 (en) | 1996-07-25 | 2001-06-05 | Cambridge Neuroscience, Inc. | Methods of treatment of eye trauma and disorders |
| AU756136B2 (en) * | 1997-06-23 | 2003-01-02 | Queen's University At Kingston | Microdose therapy |
| US20020013304A1 (en) | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| AU740758B2 (en) | 1997-10-28 | 2001-11-15 | Vivus, Inc. | Treatment of female sexual dysfunction |
| US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| US6246436B1 (en) * | 1997-11-03 | 2001-06-12 | Agilent Technologies, Inc | Adjustable gain active pixel sensor |
| TW542719B (en) * | 1998-02-23 | 2003-07-21 | Pfizer Res & Dev | Method of treating impotence due to spinal cord injury |
| US6403605B1 (en) | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| UA67802C2 (ru) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ ИНГИБИТОРА цГМФ ФДЭ-5 (ВАРИАНТЫ), СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СПОСОБ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ |
| US6613768B1 (en) | 1999-04-30 | 2003-09-02 | Lilly Icos Llc | Treatment of female arousal disorder |
| US6632419B2 (en) * | 1999-05-04 | 2003-10-14 | Aradigm Corporation | Increasing libido in humans via acute testosterone administration |
| US6428769B1 (en) | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
| US7258850B2 (en) | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
| CA2377339A1 (en) | 1999-06-17 | 2000-12-28 | Armin Johannes Becker | Administration of growth hormone (hgh) for the therapy of sexual functional disorders |
| RU2180591C2 (ru) | 1999-12-24 | 2002-03-20 | Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ | Средство для лечения сексуальных дисфункций у мужчин |
| DE10016548A1 (de) * | 2000-04-03 | 2001-10-11 | Bayer Ag | Polyurethan-Dispersionen |
| US6313172B1 (en) | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| US6242436B1 (en) * | 2000-06-15 | 2001-06-05 | William Charles Llewellyn | Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans |
| US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| JP2004524267A (ja) | 2000-08-30 | 2004-08-12 | ユニメッド・ファーマシューティカルズ・インコーポレーテッド | 男性の勃起障害の治療方法、及び性衝動の増強方法 |
| US20040092494A9 (en) | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| CA2426666A1 (en) | 2000-09-29 | 2002-04-04 | Solvay Pharmaceuticals B.V. | Ion-strength independent sustained release pharmaceutical formulation |
| US20060287335A1 (en) | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
| AU2002220977A1 (en) * | 2000-12-15 | 2002-06-24 | Pfizer Inc. | Treatment of male sexual dysfunction |
| US20020107230A1 (en) | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| WO2002069906A2 (en) | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
| KR100564466B1 (ko) | 2001-03-28 | 2006-03-29 | 화이자 인코포레이티드 | Ｆｓａｄ에 대한 ｎｅｐ 억제제로서의ｎ-펜프로필사이클로펜틸-치환된 글루타르아미드 유도체 |
| EP1260225A1 (en) * | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| US20030022875A1 (en) * | 2001-07-27 | 2003-01-30 | Wilson Leland F. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| BRPI0411985A (pt) * | 2003-07-16 | 2006-08-29 | Pfizer | tratamento da disfunção sexual |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| ES2258694T3 (es) * | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
| WO2005094827A1 (en) * | 2004-03-30 | 2005-10-13 | Kestrel Pharmaceuticals Inc. | Methods for treating sexual dysfunction |
| EP1740181A1 (en) | 2004-04-22 | 2007-01-10 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
| RS52945B (sr) * | 2004-05-11 | 2014-02-28 | Emotional Brain B.V. | Farmaceutske formulacije i njihova primena u lečenju ženske seksualne disfunkcije |
| CA2604431A1 (en) * | 2005-04-13 | 2006-10-26 | Unimed Pharmaceuticals, Inc. | Method of increasing testosterone and related steroid concentrations in women |
| WO2006127057A1 (en) | 2005-05-24 | 2006-11-30 | Lyle Corporate Drvelopment, Inc. | Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction |
| US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
| WO2007054791A2 (en) * | 2005-11-08 | 2007-05-18 | L'oréal | Androgen glucuronides as markers of androgenic activity |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| MY165575A (en) | 2007-11-28 | 2018-04-05 | Ucb Pharma Gmbh | Polymorphic form of rotigotine |
-
2006
- 2006-11-03 EP EP06076976A patent/EP1925307A1/en not_active Ceased
-
2007
- 2007-02-11 UA UAA200905652A patent/UA100119C2/ru unknown
- 2007-02-11 UA UAA200905653A patent/UA103592C2/ru unknown
- 2007-02-11 ME MEP-2016-33A patent/ME02410B/me unknown
- 2007-02-11 UA UAA200905654A patent/UA101948C2/ru unknown
- 2007-11-02 US US12/513,358 patent/US8575139B2/en not_active Expired - Fee Related
- 2007-11-02 ZA ZA200903837A patent/ZA200903837B/xx unknown
- 2007-11-02 US US12/513,355 patent/US8653051B2/en active Active
- 2007-11-02 AU AU2007314735A patent/AU2007314735B2/en not_active Ceased
- 2007-11-02 JP JP2009535226A patent/JP2010509211A/ja not_active Withdrawn
- 2007-11-02 HR HRP20160108T patent/HRP20160108T1/hr unknown
- 2007-11-02 CA CA2668317A patent/CA2668317C/en not_active Expired - Fee Related
- 2007-11-02 JP JP2009535227A patent/JP2010509212A/ja active Pending
- 2007-11-02 ZA ZA200903835A patent/ZA200903835B/xx unknown
- 2007-11-02 CN CNA2007800462422A patent/CN101557812A/zh active Pending
- 2007-11-02 HU HUE07834663A patent/HUE026752T2/en unknown
- 2007-11-02 EP EP07834663.2A patent/EP2086544B1/en active Active
- 2007-11-02 KR KR1020097011485A patent/KR20090115113A/ko not_active Ceased
- 2007-11-02 ES ES07834663.2T patent/ES2561946T3/es active Active
- 2007-11-02 MX MX2009004696A patent/MX2009004696A/es not_active Application Discontinuation
- 2007-11-02 CN CN2007800474487A patent/CN101563086B/zh not_active Expired - Fee Related
- 2007-11-02 EP EP15167346.4A patent/EP2937086A1/en not_active Withdrawn
- 2007-11-02 EP EP07834665A patent/EP2086548A2/en not_active Withdrawn
- 2007-11-02 NZ NZ577393A patent/NZ577393A/xx not_active IP Right Cessation
- 2007-11-02 MX MX2009004695A patent/MX2009004695A/es not_active Application Discontinuation
- 2007-11-02 PL PL07834663T patent/PL2086544T3/pl unknown
- 2007-11-02 NZ NZ577392A patent/NZ577392A/xx not_active IP Right Cessation
- 2007-11-02 ZA ZA200903836A patent/ZA200903836B/xx unknown
- 2007-11-02 CN CN201310556256.6A patent/CN103599536A/zh active Pending
- 2007-11-02 CA CA2668316A patent/CA2668316C/en not_active Expired - Fee Related
- 2007-11-02 CA CA2668320A patent/CA2668320C/en not_active Expired - Fee Related
- 2007-11-02 WO PCT/NL2007/050534 patent/WO2008054214A2/en not_active Ceased
- 2007-11-02 RS RS20160069A patent/RS54541B1/sr unknown
- 2007-11-02 JP JP2009535228A patent/JP2010509213A/ja active Pending
- 2007-11-02 RU RU2009120988/15A patent/RU2464027C2/ru not_active IP Right Cessation
- 2007-11-02 CN CN2013102891472A patent/CN103381270A/zh active Pending
- 2007-11-02 KR KR1020167028902A patent/KR101796887B1/ko not_active Expired - Fee Related
- 2007-11-02 BR BRPI0717963-4A2A patent/BRPI0717963A2/pt not_active IP Right Cessation
- 2007-11-02 RU RU2009120990/15A patent/RU2463054C2/ru not_active IP Right Cessation
- 2007-11-02 PT PT78346632T patent/PT2086544E/pt unknown
- 2007-11-02 AU AU2007314734A patent/AU2007314734B2/en not_active Ceased
- 2007-11-02 WO PCT/NL2007/050535 patent/WO2008054215A2/en not_active Ceased
- 2007-11-02 CN CNA2007800491317A patent/CN101573119A/zh active Pending
- 2007-11-02 KR KR1020157022168A patent/KR20150099620A/ko not_active Ceased
- 2007-11-02 BR BRPI0718396-8A2A patent/BRPI0718396A2/pt not_active IP Right Cessation
- 2007-11-02 UA UAA201214342A patent/UA115647C2/uk unknown
- 2007-11-02 MX MX2009004693A patent/MX2009004693A/es active IP Right Grant
- 2007-11-02 BR BRPI0717856-5A2A patent/BRPI0717856A2/pt active Search and Examination
- 2007-11-02 KR KR1020097011486A patent/KR20090111803A/ko not_active Ceased
- 2007-11-02 KR KR1020097011483A patent/KR101578224B1/ko not_active Expired - Fee Related
- 2007-11-02 US US12/513,357 patent/US8648060B2/en active Active
- 2007-11-02 AU AU2007314736A patent/AU2007314736B2/en not_active Ceased
- 2007-11-02 EP EP07834664A patent/EP2086545A2/en not_active Withdrawn
- 2007-11-02 NZ NZ577390A patent/NZ577390A/xx not_active IP Right Cessation
- 2007-11-02 SI SI200731745T patent/SI2086544T1/sl unknown
- 2007-11-02 RU RU2009120992/15A patent/RU2491073C2/ru not_active IP Right Cessation
- 2007-11-02 CN CN201410844093.6A patent/CN104524580A/zh active Pending
- 2007-11-02 KR KR20157004613A patent/KR20150038251A/ko not_active Ceased
- 2007-11-02 DK DK07834663.2T patent/DK2086544T3/en active
- 2007-11-02 WO PCT/NL2007/050533 patent/WO2008054213A2/en not_active Ceased
-
2009
- 2009-04-30 IL IL198459A patent/IL198459A/en active IP Right Grant
- 2009-04-30 IL IL198461A patent/IL198461A/en active IP Right Grant
- 2009-04-30 IL IL198460A patent/IL198460A/en active IP Right Grant
- 2009-06-03 NO NO20092145A patent/NO20092145L/no not_active Application Discontinuation
- 2009-06-03 NO NO20092146A patent/NO20092146L/no not_active Application Discontinuation
- 2009-06-03 NO NO20092143A patent/NO343597B1/no not_active IP Right Cessation
-
2012
- 2012-06-20 RU RU2012125827A patent/RU2646447C2/ru not_active IP Right Cessation
- 2012-07-10 US US13/545,916 patent/US8669242B2/en active Active
-
2013
- 2013-09-06 JP JP2013185156A patent/JP5748238B2/ja not_active Expired - Fee Related
- 2013-10-08 US US14/049,005 patent/US9211334B2/en not_active Expired - Fee Related
- 2013-10-16 JP JP2013215284A patent/JP2014055142A/ja active Pending
-
2014
- 2014-01-03 US US14/147,393 patent/US20140121189A1/en not_active Abandoned
- 2014-01-03 US US14/147,415 patent/US20140121190A1/en not_active Abandoned
- 2014-01-08 JP JP2014001289A patent/JP2014111608A/ja active Pending
- 2014-06-20 PH PH12014501440A patent/PH12014501440A1/en unknown
- 2014-08-12 PH PH12014501821A patent/PH12014501821B1/en unknown
-
2015
- 2015-03-16 IL IL237786A patent/IL237786A0/en unknown
- 2015-05-07 JP JP2015094573A patent/JP6357131B2/ja not_active Expired - Fee Related
- 2015-12-04 US US14/960,204 patent/US9597335B2/en not_active Expired - Fee Related
-
2016
- 2016-02-12 CY CY20161100116T patent/CY1117191T1/el unknown
- 2016-10-27 IL IL248563A patent/IL248563B/en active IP Right Grant
-
2017
- 2017-02-21 US US15/438,547 patent/US10314848B2/en not_active Expired - Fee Related
- 2017-05-10 JP JP2017093563A patent/JP2017132809A/ja active Pending
-
2019
- 2019-05-14 US US16/412,276 patent/US20190262359A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009120990A (ru) | Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
| CY1114448T1 (el) | Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας | |
| HN2004000490A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente | |
| AR077199A1 (es) | Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia | |
| MX2013000001A (es) | Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. | |
| EA200601654A1 (ru) | Ингибиторы интегразы вич | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| EA200501268A1 (ru) | Ингибирующие вич 1,2,4-триазины | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
| NZ593199A (en) | Milnacipran for the long-term treatment of fybromyalgia syndrome | |
| CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. | |
| PA8586301A1 (es) | Formulaciones de liberacion prolongada en forma de suspension | |
| CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. | |
| MD4093B1 (ru) | Применение фармацевтической композиции для местного применения содержащей амброксол | |
| DE602004019528D1 (de) | Usammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle | |
| MXPA05008403A (es) | Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion. | |
| UA102111C2 (ru) | Фармацевтическая композиция в виде разовой пероральной дозы, которая содержит леводопу, карбидопу и энтакапон или их соли | |
| AR052322A1 (es) | Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica | |
| PL2020999T3 (pl) | Kompozycje zawierające alfa-ketoglutaran i ich zastosowanie do modulowania wydajności mięśniowej | |
| CL2008002223A1 (es) | Compuestos derivados de 9-desoxo-9a-metil-9a-aza-9a-homoeritromicina a 2'-o-sustituida; proceso de preparación; compuesto intermediario; composición farmacéutica; y su uso en el tratamiento y/o profilaxis de la malaria. | |
| PA8789101A1 (es) | Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20150505 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201103 |